- |||||||||| lisinopril / Generic mfg.
Trial completion date, Trial primary completion date: Optimal Management of HIV Infected Adults at Risk for Kidney Complications in Nigeria (clinicaltrials.gov) - Jun 13, 2019
P2, N=280, Not yet recruiting,
A careful review for pharmacologic interactions should be performed prior to intracavernosal phenylephrine administration, and close monitoring should occur after its administration. Trial completion date: Aug 2022 --> Aug 2023 | Trial primary completion date: Feb 2022 --> Feb 2023
- |||||||||| rosuvastatin / generics, AstraZeneca
Clinical, Journal, Combination therapy: The effect of changing of conventional antihypertensive therapy to a triple fixed combination therapy with rosuvastatin in high cardiovascular risk patients (Pubmed Central) - May 24, 2019
113 patients with atherosclerosis of brachiocephalic arteries (BCA) receiving antihypertensive and partially taking statins therapy were assessed cholesterol, low-density lipoprotein cholesterol (LDL-C), peripheral and central blood pressure, carotid-femoral pulse wave velocity (PWV) initially and after 12 months of taking amlodipine + lisinopril + rosuvastatin (A+L+R) SPCs. The administration of A+L+R SPCs for 12 months was associated with an increasing of number of patients with the achieved target blood pressure.
- |||||||||| amlodipine/rosuvastatin (DP-R212) / Alvogen
Journal: Lisinopril, Amlodipine, Rosuvastatin as a Novel Fixed Combination in the Fight Against Cardiovascular Disease (Pubmed Central) - May 17, 2019
The efficacy of each of the components and their combined administration in primary and secondary prevention of cardiovascular disease has been demonstrated in clinical studies. The convenience of several drugs combination in a single tablet increases adherence to therapy facilitating regular intake of all treatment components and reliably reducing the risk of cardiovascular complications.
- |||||||||| lisinopril / generics
Journal: Lizinopril in the Treatment of Arterial Hypertension (Pubmed Central) - May 17, 2019
Among large number of representatives of this class lisinopril deserves special attention as one of best known and well-studied ACEIs. Wide spectrum of activity and proven organoprotective qualities of lisinopril allow to use it a variety of situations.
- |||||||||| lisinopril / generics
Lisinopril. (Twitter) - May 15, 2019
- |||||||||| Entresto (sacubitril/valsartan) / Novartis, Laboratorios Farmaceuticos Rovi
Clinical, Journal: Adoption of Sacubitril/Valsartan for the Management of Patients With Heart Failure. (Pubmed Central) - May 8, 2019
Wide spectrum of activity and proven organoprotective qualities of lisinopril allow to use it a variety of situations. Adoption of sacubitril/valsartan after Food and Drug Administration approval has been slow and may be associated with the high cost.
- |||||||||| Telmitan (telmisartan) / Orient Europharma
Journal: IMPROVEMENT OF TREATMENT IN PERSONS WITH ARTERIAL HYPERTENSION AND TYPE 2 DIABETES MELLITUS. (Pubmed Central) - May 2, 2019
In coexistent patients with greater than 10 pg/ml level of endothelin-1 and 80 mg/day dose of telmisartan, the level of albumin excretion rate was reduced by 4,9% (p=0,0435), and left ventricular mass index - by 3,1% (p<0,0001). If the level of this indicator is less than 10 pg/ml, the dose of telmisartan is 40 mg/day, if the level of endothelin-1 is more than 10 pg/ml, the dose of telmisartan is 80 mg/day.
- |||||||||| NN1213 / Novo Nordisk
Trial termination, Surgery: OPTMIZE-OS: Risk Factor Control Before Orthopedic Surgery (clinicaltrials.gov) - Apr 29, 2019
P4, N=198, Terminated,
If the level of this indicator is less than 10 pg/ml, the dose of telmisartan is 40 mg/day, if the level of endothelin-1 is more than 10 pg/ml, the dose of telmisartan is 80 mg/day. Suspended --> Terminated; Low recruitment / DSMB approval to halt recruitment
- |||||||||| lisinopril / generics
Clinical, Journal: Unusual Case of a Massive Macroglossia Secondary to Myxedema: A Case Report and Literature Review. (Pubmed Central) - Apr 26, 2019
...Substantial enlargement of the tongue (16 cm long × 10 cm wide) was first attributed to angioedema, which was refractory to the discontinuation of lisinopril and a C1 esterase inhibitor...She recovered unremarkably, with excellent cosmesis and preservation of lingual and hypoglossal function. There are some case reports of massive macroglossia but none with myxedema as the primary etiology.
- |||||||||| Tamoxis (tamoxifen) / Bioprofarma, Tekturna (aliskiren) / PDL
Journal: Attenuation of Accelerated Renal Cystogenesis in Pkd1 Mice by Renin Angiotensin System Blockade. (Pubmed Central) - Apr 26, 2019
There are some case reports of massive macroglossia but none with myxedema as the primary etiology. These results indicate that suppressing Agt using an ASO slowed the progression of accelerated cystic kidney disease induced by unilateral nephrectomy in Pkd1 mice by suppressing intrarenal RAS, mTOR pathway and cell proliferation.
- |||||||||| Herceptin (trastuzumab) / Roche
Trial completion, Adverse events: Lisinopril or Coreg CR (clinicaltrials.gov) - Apr 26, 2019
P2, N=468, Completed,
These results indicate that suppressing Agt using an ASO slowed the progression of accelerated cystic kidney disease induced by unilateral nephrectomy in Pkd1 mice by suppressing intrarenal RAS, mTOR pathway and cell proliferation. Active, not recruiting --> Completed
- |||||||||| lisinopril / generics, spironolactone / generics
Journal, Combination therapy: Photocurable Bioinks for the 3D Pharming of Combination Therapies. (Pubmed Central) - Apr 10, 2019
High-performance liquid chromatography (HPLC) analysis showed sustained release profiles for each of the loaded compounds. This study confirms the potential of material jetting in conjunction with binder jetting techniques (powder-bed 3D printing), for the production of combination therapy oral dosage forms involving both hydrophilic and hydrophobic drugs.
- |||||||||| Frumeron (indapamide) / Remedica
Clinical, Journal: 'Temporary Plasticiser': A Novel Solution to Fabricate 3D Printed Patient-Centred Cardiovascular 'Polypill' Architectures. (Pubmed Central) - Apr 7, 2019
In addition to the multilayer architecture offering a higher flexibility in dose titration and a more adaptive solution to meet the expectations of patient-centred therapy, we identify that it also allows orchestrating the release of drugs of different physicochemical characteristics. Adopting such an approach opens up a pathway towards low-cost multidrug delivery systems such as tablets, stents or implants for wider range of globally approved actives.
- |||||||||| lisinopril / generics
Next steps: A 36 year old male w/HTN on ASA and lisinopril, EKG normal. His Lipid profile, CardioIQ TC 253, LDL 176, LDL small 543, LDL pattern B, Apo B 134, Lipoprotein A 120, HS CRP 1.5. What are next steps to prevent MI, beside dietary counseling, statin, etc. Thanks! (Twitter) - Mar 26, 2019
- |||||||||| enalapril / generics, lisinopril / generics, eplerenone / generics
Retrospective data, Journal: Pharmacological Treatment of Arterial Hypertension in Children and Adolescents: A Network Meta-Analysis. (Pubmed Central) - Mar 23, 2019
According to the present analysis, angiotensin-converting enzyme inhibitors and angiotensin receptor blockers could represent the best choice as antihypertensive treatment for pediatric hypertension. However, because of the paucity of available data for the other classes of antihypertensive drugs, definitive conclusions are not allowed and further randomized controlled trials are warranted.
- |||||||||| lisinopril / generics, fosinopril / generics
Journal: A method using angiotensin converting enzyme immobilized on magnetic beads for inhibitor screening. (Pubmed Central) - Mar 21, 2019
As a result, epiberberine and fangchinoline with certain ACE inhibitory activities were screened out in the assay and validated. The results demonstrate the usefulness of this screening method using ACE immobilized on magnetic beads and the advantage of great efficiency with respect to both time and reagents for screening ACE inhibitors.
- |||||||||| lercanidipine / Generic mfg., furosemide / Generic mfg., lisinopril / Generic mfg.
Trial completion date, Trial primary completion date: Effect of RAS Blockers on CKD Progression in Elderly Patients With Non Proteinuric Nephropathies (PROERCAN01) (clinicaltrials.gov) - Feb 22, 2019
P4, N=106, Recruiting,
The results demonstrate the usefulness of this screening method using ACE immobilized on magnetic beads and the advantage of great efficiency with respect to both time and reagents for screening ACE inhibitors. Trial completion date: Jun 2021 --> Dec 2022 | Trial primary completion date: Jun 2018 --> Dec 2019
- |||||||||| candesartan cilexetil / Generic mfg., lisinopril / Generic mfg.
Trial completion: CALIBREX: CAndesartan vs LIsinopril Effects on the BRain (clinicaltrials.gov) - Jan 24, 2019
P3, N=176, Completed,
Trial completion date: Jun 2021 --> Dec 2022 | Trial primary completion date: Jun 2018 --> Dec 2019 Active, not recruiting --> Completed
- |||||||||| lisinopril / Generic mfg.
Trial completion date, Trial initiation date, Trial primary completion date: Clinical Bioequivalence Study on Two Lisinopril Tablets 20mg Formulations (clinicaltrials.gov) - Jan 16, 2019
P1, N=30, Not yet recruiting,
Active, not recruiting --> Completed Trial completion date: Apr 2019 --> Apr 2020 | Initiation date: Oct 2018 --> Oct 2019 | Trial primary completion date: Mar 2019 --> Mar 2020
- |||||||||| lisinopril / Generic mfg.
Trial completion date, Trial initiation date, Trial primary completion date: A Pilot Study: Preventing Adverse Remodelling Following Pacemaker Implantation (clinicaltrials.gov) - Nov 28, 2018
P2, N=75, Not yet recruiting,
N=550 --> 4422 Trial completion date: Sep 2020 --> Sep 2021 | Initiation date: Jul 2018 --> Jul 2019 | Trial primary completion date: Jul 2020 --> Jul 2021
- |||||||||| lisinopril / Generic mfg.
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: Dose Titration of Lisinopril in Children Aged 1 to 18 Years With Primary or Secondary Hypertension (clinicaltrials.gov) - Sep 20, 2018
P4, N=13, Completed,
Trial completion date: Sep 2020 --> Sep 2021 | Initiation date: Jul 2018 --> Jul 2019 | Trial primary completion date: Jul 2020 --> Jul 2021 Recruiting --> Completed | N=33 --> 13 | Trial completion date: Jan 2016 --> Sep 2018 | Trial primary completion date: Sep 2015 --> May 2017
- |||||||||| Enrollment change, Trial completion date, Trial initiation date, Trial primary completion date: REMAP-CAP: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (clinicaltrials.gov) - Aug 20, 2018
P4, N=6800, Recruiting,
Recruiting --> Completed | Trial completion date: Dec 2020 --> Jun 2018 | Trial primary completion date: Jun 2020 --> Jun 2018 N=4000 --> 6800 | Trial completion date: Feb 2019 --> Jun 2022 | Trial primary completion date: Feb 2019 --> Dec 2021 | Initiation date: Dec 2015 --> Apr 2016
- |||||||||| lisinopril / Generic mfg.
Trial completion date, Trial primary completion date: Lisinopril in Reducing Shortness of Breath Caused by Radiation Therapy in Patients With Lung Cancer (clinicaltrials.gov) - Aug 14, 2018
P=N/A, N=50, Active, not recruiting,
N=4000 --> 6800 | Trial completion date: Feb 2019 --> Jun 2022 | Trial primary completion date: Feb 2019 --> Dec 2021 | Initiation date: Dec 2015 --> Apr 2016 Trial completion date: Jul 2018 --> Nov 2018 | Trial primary completion date: Jul 2018 --> Nov 2018
- |||||||||| lisinopril / Generic mfg.
Trial completion, Enrollment change: Clinical Trial of Coenzyme Q10 and Lisinopril in Muscular Dystrophies (clinicaltrials.gov) - Jun 15, 2018
P2/3, N=63, Completed,
Our RNA-Seq analysis suggests that ASI reduce the malignant potential of cancer cells and stimulate the immune microenvironment in primary PDAC. Enrolling by invitation --> Completed | N=120 --> 63
- |||||||||| Hygroton (chlortalidone) / Alliance, NN1213 / Novo Nordisk
Phase classification: Genetics of Hypertension Associated Treatments (GenHAT) (clinicaltrials.gov) - Apr 6, 2018
P, N=37939, Completed,
Enrolling by invitation --> Completed | N=120 --> 63 Phase classification: P=N/A --> P
- |||||||||| atorvastatin / Generic mfg., lisinopril / Generic mfg.
Trial completion date, Trial suspension, Trial primary completion date, Surgery: OPTMIZE-OS: Risk Factor Control Before Orthopedic Surgery (clinicaltrials.gov) - Mar 14, 2018
P4, N=198, Suspended,
Phase classification: P=N/A --> P Trial completion date: May 2017 --> Dec 2018 | Terminated --> Suspended | Trial primary completion date: May 2017 --> Dec 2018
- |||||||||| Bystolic (nebivolol) / Menarini, AbbVie
Trial completion, Trial completion date: FINE-PATH: Non-invasive Haemodynamic Assessment in Hypertension (clinicaltrials.gov) - Mar 13, 2018
P=N/A, N=144, Completed,
Trial completion date: May 2017 --> Dec 2018 | Terminated --> Suspended | Trial primary completion date: May 2017 --> Dec 2018 Recruiting --> Completed | Trial completion date: Dec 2015 --> Dec 2017
- |||||||||| lisinopril / Generic mfg.
Trial completion date, Trial initiation date, Trial primary completion date: Prophylactic Lisinopril to Prevent Anthracycline Cardiomyopathy. (clinicaltrials.gov) - Mar 3, 2018
P4, N=200, Not yet recruiting,
Phase classification: P=N/A --> P3 Trial completion date: Dec 2019 --> Mar 2020 | Initiation date: Jan 2018 --> Mar 2018 | Trial primary completion date: Jan 2019 --> Mar 2019
|
